{"id":"NCT04753710","sponsor":"Sintetica SA","briefTitle":"Efficacy, Safety and Tolerability Study of Chloroprocaine 3% Gel Eye Drops in Healthy Volunteers","officialTitle":"A Phase II/III, Randomized, Double-Masked, Vehicle-Controlled, Efficacy, Safety and Tolerability Study of Chloroprocaine 3% Gel Eye Drops in Healthy Volunteers","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2020-06-29","primaryCompletion":"2020-11-06","completion":"2020-12-09","firstPosted":"2021-02-15","resultsPosted":"2022-01-24","lastUpdate":"2022-03-17"},"enrollment":96,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Healthy Volunteers"],"interventions":[{"type":"DRUG","name":"Ocular gel","otherNames":[]}],"arms":[{"label":"Chloroprocaine","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The study assess efficacy, safety and tolerability of Chloroprocaine 3% ophthalmic gel in healthy volunteers.","primaryOutcome":{"measure":"Number of Participants in Phase 2 With Anesthesia Success","timeFrame":"Day 1","effectByArm":[{"arm":"Chloroprocaine","deltaMin":38,"sd":null},{"arm":"Placebo","deltaMin":4,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["Austria"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":67},"commonTop":["mydriasis","eye irritation","Headache","bradycardia","Sensation of foreign body"]}}